Evidence map›Paper›PMID 42093597›Full record

ArticleDevelopment (Cambridge, England)2026

Regulation of endothelial cell chromatin availability and transcription factor activity during arterial-venous specification.

Nicholas W Chavkin, Elizabeth A Nelson, Grace Bradecamp, Jordon W Aragon, Lay Teng Ang, Kyle M Loh, Karen K Hirschi

Abstract read
In one paragraph

Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nicholas W ChavkinCenter for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Elizabeth A NelsonDepartment of Cell Biology and Developmental Genomics Center, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Grace BradecampDepartment of Cell Biology and Developmental Genomics Center, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Jordon W AragonDepartment of Cell Biology and Developmental Genomics Center, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Lay Teng AngInstitute for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.
Kyle M LohInstitute for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.
Karen K HirschiDepartment of Cell Biology and Developmental Genomics Center, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.ORCID 0000-0001-7116-0130

Funding

miR-223 regulates endothelial to hematopoietic transitionR01DK118728 · NIDDK · YALE UNIVERSITY · PI HIRSCHI, KAREN KEMPER, NICOLI, STEFANIA · 2020 to 2023
$2.9M
Cell Cycle Control of Arterial-Venous SpecificationR01HL171284 · NHLBI · UNIVERSITY OF VIRGINIA · PI Karen Kemper Hirschi · 2024 to 2026
$2.3M
Endothelial Cell Cycle State and Cell FateR01HL146056 · NHLBI · UNIVERSITY OF VIRGINIA · PI HIRSCHI, KAREN KEMPER · 2019 to 2022
$2.1M
The Role of Hematopoietic Loss of Y Chromosome on Aging PhenotypesK22AG081323 · NIA · SEATTLE CHILDREN'S HOSPITAL · PI Nicholas W Chavkin · 2024 to 2026
$559k
Cell Cycle Control Of Arterial-Venous Specification Within the Developing EmbryoF31HL172647 · NHLBI · UNIVERSITY OF VIRGINIA · PI ARAGON, JORDON · 2024 to 2025
$77k
American Heart Association 23CDA1054358American Heart Association-American Stroke Association 23CDA1054358NHLBI NIH HHS F31 HL172647NHLBI NIH HHS F31HL172647NHLBI NIH HHS R01 HL146056NHLBI NIH HHS R01HL146056NHLBI NIH HHS R01 HL171284NHLBI NIH HHS R01HL171284NIA NIH HHS K22 AG081323NIA NIH HHS K22AG081323NIDDK NIH HHS R01 DK118728NIDDK NIH HHS R01DK118728NIH HHS F31HL172647NIH HHS K22AG081323NIH HHS R01DK118728NIH HHS R01HL146056NIH HHS R01HL171284
6 · The paper itself

Abstract

Arterial-venous specification of endothelial cells during vascular development requires coordination between intracellular signaling, cell cycle state and transcription factor activity. However, the intrinsic regulatory mechanisms that govern these processes are poorly understood. To investigate this, we assessed endothelial chromatin accessibility during vascular development. Murine postnatal day (P) 6 and P15 retinal endothelial cells were analyzed by single cell assay for transposase accessible chromatin sequencing, revealing heterogeneous chromatin accessibility across an arterial-venous continuum and in distinct cell cycle states. Enhancer regulatory network analysis predicted transcription factors with differential cell cycle and arterial-venous activity, and many with dual activator and repressor functions, including SOX17. We then validated SOX17 function in human endothelial cells, identifying that it inhibits proliferation and promotes arterial gene expression. Our findings suggest that dual roles of key endothelial transcription factors are regulated by chromatin accessibility in a cell cycle- and subtype-specific manner to control arterial-venous specification.

Indexed as

ArteriesChromatinEndothelial CellsTranscription FactorsVeinsAnimalsCell CycleCell ProliferationGene Expression Regulation, DevelopmentalHMGB ProteinsHumansMiceSOXF Transcription FactorsChromatinHMGB ProteinsSox17 protein, mouseSOXF Transcription FactorsTranscription FactorsArterial-venous specificationCell cycle controlChromatin accessibilityEndothelial cellsTranscription factor activityVascular development

Identifiers

PMID42093597
PMCPMC13349086

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.